. Author manuscript; available in PMC: 2018 Aug 15.

Published in final edited form as: J Acquir Immune Defic Syndr. 2017 Aug 15;75(5):535–539. doi: 10.1097/QAI.0000000000001440

Table 2.

Most commonly reported adverse events among Quad Pill PEP participants versus those using other PEP regimens, Fenway Health, Boston, 2000–2015

	AZT/3TC/PI¹ (N = 119) % (N)	TDF/FTC+RAL² (N = 100) % (N)	QUAD Pill³ (N= 100) % (N)

Recruited	Jan 2000 – May 2004	Mar 2008 – Mar 2010	May 2013 – Nov 2015

Diarrhea	58.8 (70)⁴	21.0 (21)⁴	38.0 (38)
Fatigue	48.5 (54)⁴	14.0 (14)⁵	28.0 (28)
Nausea/vomiting	58.8 (70)⁶	27.0 (27)	28.0 (28)
Headache	11.8 (14)	15.0 (15)	14.0 (14)
Dizziness/Lightheadedness	8.4 (10)	10.0 (10)	6.0 (6)
Body/muscle/joint pain or aches and/or overall discomfort	10.9 (13)⁴	8.0 (8)⁵	2.0 (2)

Quad Pill = referent

^{^}

Includes abdominal cramping, excessive gas, upset stomach, stomach ache

AZT/3TC/PI = Zidovudine/Lamivudine/Protease Inhibitor

TDF/FTC+RAL = Tenofovir disoproxil fumarate coformulated with emtricitabine plus raltegravir bid

QUAD Pill = tenofovir disoproxil fumarate, emtricitabine, elvitegravir, cobicistat coformulated

⁴

p<.05

⁵

p<.01

⁶

p<.001